Fidelity Investments
CRNX icon

Fidelity Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

Fidelity Investments’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$572M Buy
15,759,799
+1,466,024
+10% +$65.5M 0.03% 464
2025
Q4 		$665M Buy
14,293,775
+106,277
+0.7% +$4.73M 0.03% 409
2025
Q3 		$591M Buy
14,187,498
+61,499
+0.4% +$1.97M 0.03% 436
2025
Q2 		$406M Buy
14,125,999
+94,730
+0.7% +$2.93M 0.02% 570
2025
Q1 		$471M Buy
14,031,269
+5,103,183
+57% +$191M 0.03% 478
2024
Q4 		$456M Buy
8,928,086
+4,472,316
+100% +$250M 0.03% 507
2024
Q3 		$228M Buy
4,455,770
+358,975
+9% +$18.5M 0.01% 784
2024
Q2 		$183M Sell
4,096,795
-366,881
-8% -$16.9M 0.01% 812
2024
Q1 		$209M Buy
4,463,676
+419,811
+10% +$16.4M 0.01% 770
2023
Q4 		$144M Buy
4,043,865
+1,903,004
+89% +$58.4M 0.01% 878
2023
Q3 		$63.7M Buy
2,140,861
+1,057,947
+98% +$21.8M 0.01% 1161
2023
Q2 		$19.5M Buy
1,082,914
+161,956
+18% +$3.23M ﹤0.01% 1646
2023
Q1 		$14.8M Sell
920,958
-962,160
-51% -$17.8M ﹤0.01% 1736
2022
Q4 		$34.5M Sell
1,883,118
-798,485
-30% -$14.1M ﹤0.01% 1404
2022
Q3 		$52.7M Sell
2,681,603
-305,417
-10% -$6.23M 0.01% 1228
2022
Q2 		$55.7M Sell
2,987,020
-350,375
-10% -$6.99M 0.01% 1209
2022
Q1 		$73.3M Sell
3,337,395
-384,900
-10% -$7.79M 0.01% 1219
2021
Q4 		$106M Sell
3,722,295
-704,139
-16% -$17.4M 0.01% 1078
2021
Q3 		$93.2M Sell
4,426,434
-692,514
-14% -$14.5M 0.01% 1130
2021
Q2 		$96.5M Buy
5,118,948
+180,632
+4% +$3.17M 0.01% 1134
2021
Q1 		$75.5M Sell
4,938,316
-33
-0% -$511 0.01% 1200
2020
Q4 		$69.7M Buy
4,938,349
+5,833
+0.1% +$81.2K 0.01% 1189
2020
Q3 		$77.3M Buy
4,932,516
+5,681
+0.1% +$86.8K 0.01% 1036
2020
Q2 		$86.3M Buy
4,926,835
+1,488,535
+43% +$25.4M 0.01% 932
2020
Q1 		$50.5M Sell
3,438,300
-195,031
-5% -$4M 0.01% 1025
2019
Q4 		$91.2M Buy
3,633,331
+7,320
+0.2% +$139K 0.01% 946
2019
Q3 		$54.5M Buy
3,626,011
+5,310
+0.1% +$103K 0.01% 1130
2019
Q2 		$90.5M Buy
3,620,701
+6,413
+0.2% +$159K 0.01% 955
2019
Q1 		$82.3M Buy
3,614,288
+675,749
+23% +$16.6M 0.01% 985
2018
Q4 		$88.1M Buy
2,938,539
+220,701
+8% +$6.21M 0.01% 909
2018
Q3 		$77.9M Buy
+2,717,838
New +$80.7M 0.01% 1058

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments's CRNX Position: Q1 2026 in Review

Fidelity Investments increased its Crinetics Pharmaceuticals (CRNX) stake by 10% in Q1 2026, buying an estimated $65.5M and bringing the position to 15,759,799 shares worth $572M. The position accounts for 0.03% of the portfolio, ranked #464.

Fidelity Investments first reported a position in CRNX in Q3 2018 and has held it in 31 quarters since. The position peaked at $665M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Fidelity Investments held 15,759,799 shares of Crinetics Pharmaceuticals worth $572M as of Q1 2026.
  • Fidelity Investments bought 1,466,024 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $65.5M.
  • Crinetics Pharmaceuticals made up 0.03% of Fidelity Investments's portfolio in Q1 2026, its #464 holding.
  • Fidelity Investments first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Fidelity Investments's Crinetics Pharmaceuticals position peaked at $665M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.